|
HCV3 for Multiple Indications involving Alpha2B Receptor Modulation
The invention is a preclinical drug candidate (HCV3) based on the discovery that substituted 1-arylalkyl-4-acylaminopiperide compounds have shown to be effective antagonists of mu-, delta-, and kappa-opioid receptors and/or alpha-2-adrenoreceptors. HCV3 can be used to treat clinical conditions that are due to activation of any one or more of the receptors,...
Published: 3/12/2024
|
Inventor(s): Victor Hruby, Ruben Vardanyan
Keywords(s):
Category(s): Technology Classifications > Life Sciences > Small Molecules, Technology Classifications > Life Sciences > Therapeutics
|
|
Substituted 1-Arylethyl-4-Acylaminopiperidine Derivatives for the Treatment of Multiple Indications in which Mu Opiod and Alpha2B Adenoreceptors are Involved
This invention is a therapeutic treatment for levodopa-induced dyskinesia. This treatment utilizes Opioid/Alpha-adrenoreceptor modulators derived from the fentanyl series of drug compounds.
Background:
Levodopa is a widely prescribed, effective treatment for the symptoms of Parkinson’s Disease. However, within five years of treatment about...
Published: 3/12/2024
|
Inventor(s): Victor Hruby, Ruben Vardanyan
Keywords(s):
Category(s): Technology Classifications > Life Sciences > Small Molecules
|
|
Small Molecule Therapeutics for L-DOPA-Induced Dyskinesia
This invention provides a novel therapeutic for the reduction of levodopa-induced dyskinesia associated with the treatment of Parkinson’s disease. This invention has been demonstrated to have a statistically significant effect upon dyskinesia compared to amantadine, the only drug currently given for dyskinesia treatment. This invention is for...
Published: 6/20/2024
|
Inventor(s): Ruben Vardanyan, Victor Hruby
Keywords(s): pain
Category(s): Technology Classifications > Life Sciences > Therapeutics
|
